Why Novartis AG’s (NVS) Stock Is Down 12.46%
As of Tuesday, September 08, Novartis AG’s NVS share price has dipped by 12.46%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Commentary & Analysis
Why Novartis AG’s (NVS) Stock Is Down 13.78%
As of Tuesday, September 08, Novartis AG’s NVS share price has dipped by 13.78%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Novartis AG’s (NVS) Stock Is Up 6.44%
As of Tuesday, September 01, Novartis AG’s NVS share price has surged by 6.44%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Is Novartis AG (NVS) Overvalued?
We dive into why Novartis AG (NVS) could be considered overvalued on 2026-07-14, based on AAII’s Value Score and Grade.Tudor Pop
Is Novartis AG (NVS) Overvalued?
We dive into why Novartis AG (NVS) could be considered overvalued on 2026-07-13, based on AAII’s Value Score and Grade.Michael Rose
Financial Summary
| Share Statistics | NVS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $266,507.4 | $494.5 | 99% |
|
| Shares Out (Mil) | 1,914.0 | 42.5 | 97% |
|
| Institutional Ownership | 99.7% | 84.1% | 92% |
|
| Float (Mil) | 1,856.4 | 45.1 | 95% |
|
| Beta | 0.49 | 0.71 | 28% |
|
| Avg Daily Volume (000s) | 1,942 | 383 | 81% |
|
| Price Change (52-week) |
7.1% | 60.3% | 59% |
|
| Growth | NVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 2.6% | 6.1% | 26% |
|
| Net Income (5yr) | 11.6% | (1.6%) | 58% |
|
| EPS (5yr) | 15.2% | 15.1% | 57 |
|
| Dividends (5yr) | 6.6% | 0.0% | 97% |
|
| Cash Flow (5yr) | 56.5% | (15.1%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 9 | 10 | |
| Current EPS | $2.227 | $8.848 | $9.837 | |
| Month Ago EPS | $2.230 | $8.803 | $9.816 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | $2.244 | $8.741 | $9.796 | |
| Year/Year Chg | 30.2% | 23.7% | 50.6% | |
| Financials | NVS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $56,693 | $364 | 97% |
|
| Net Income (TTM) (Mil) | $12,757 | ($11) | 99% |
|
| EPS (TTM) | $6.669 | ($0.700) | 90% |
|
| Operating Cash Flow (TTM) (Mil) | $18,393 | ($7) | 99% |
|
| Net Cash Flow (TTM) (Mil) | $960 | $6 | 94% |
|
| Long-Term Debt (Q1) (Mil) | $39,152 | $6 | 98% |
|
| Enterprise Value (Q1) (Mil) | $334,681 | $493 | 99% |
|
| Valuation | NVS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 6.45 | 2.33 | 84% |
|
| P/E | 21.3 | 17.3 | 57% |
|
| Dividend Yield | 3.4% | 0.0% | 86% |
|
| PEG (5yr hist) | 1.4 | 1.1 | 59% |
|
| Ratios | NVS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.0% | 68.8% | 85% |
|
| Net Margin | 22.5% | 3.0% | 81% |
|
| ROA | 11.3% | (22.2%) | 89% |
|
| ROE | 30.5% | (21.4%) | 87% |
|
| Liabilities to Assets | 65.6% | 33.9% | 61% |
|
| F-Score | 5 | 3 | 50% |
|
Novartis AG did not pass any screens on 10/2/2026.
